Skye Bioscience Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March31, 2026 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number:000-55136 Skye Bioscience, Inc._____________________________________________________________ (Exact name of registrant as specified in its charter) (State or other jurisdictionof incorporation or organization) 11250 El Camino Real, Suite 100,San Diego, CA 92130(Address of principal executive offices) (Zip Code) (858) 410-0266(Registrant’s telephone number, including area code) __________________________N/A_______________________________(Former name, former address and former fiscal year, if changed since last report)Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchangeon which registeredCommon Stock, par value $0.001SKYENasdaq Global Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No As of May8, 2026, there were 35,143,722shares of the registrant's common stock, $0.001 par value, issued and outstanding. TABLE OF CONTENTS PART I - FINANCIAL INFORMATION Item 1.Financial Statements:4Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 20255Condensed Consolidated Statements of Operations for theThree Months Ended March 31, 2026 and 2025(Unaudited)6Condensed Consolidated Statements of Cash Flows for theThree Months Ended March 31, 2026 and 2025(Unaudited)7Condensed Consolidated Statements of Stockholders’ Equity for theThree Months Ended March 31, 2026 and2025(Unaudited)8Notes to the Unaudited Condensed Consolidated Financial Statements9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosures about Market Risk25Item 4.Controls and Procedures25 PART II - OTHER INFORMATION Item 1.Legal Proceedings26Item 1A.Risk Factors26Item 2.Unregistered Sales of Equity Securities and Use of Proceeds26Item 3.Defaults Upon Senior Securities26Item 4.Mine Safety Disclosures26Item 5.Other Information26Item 6.Exhibits27 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities LitigationReform Act of 1995. All statements other than statements of historical facts included in this Quarterly Report are forward-lookingstatements, including without limitation, statements regarding: •the period over which we estimate our existing cash, cash equivalents and short-term investments will be sufficient to fundour future operating expenses and capital expenditure requirements, including that our existing cash, cash equivalent, andmarketable securities will be sufficient to fund our obligations for at least 12 months after the issuance of the condensedconsolidated financial statements included in this report;•the timing, progress and results of preclinical studies and clinical studies for nimacimab (such as the extension arm of ourPhase 2a CBeyondTM clinical trial), including any future studies or plans to evaluate combinations of nimacimab andincretin-based therapies;•the timing, scope and likelihood of regulatory filings and approvals;•expectations regarding the size, scope and design of future clinical studies;•our manufacturing, commercialization, and marketing plans and strategies;•ou